Adaptimmune Therapeutics Azioni (NASDAQ: ADAP)

Ultime notizie per Adaptimmune Therapeutics (NASDAQ:ADAP) Azioni

Adaptimmune Therapeutics

Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70 and others for multiple cancer types.

Adaptimmune Therapeutics plc - American Depositary Shares

Adaptimmune Therapeutics PLC

ADAPad

Adappter Token

AdaptHealth Corp

ADAPTIVE AD SYSTEMS INC by Adaptive Ad Systems, Inc.

Adaptive Ad Systems Inc

Adaptive Alpha Opportunities ETF

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies Corp

Adaptive Core ETF

Adaptive Hedged Multi-Asset Income ETF

HC Wainwright &amp; Co. analyst Arthur He reiterates Adaptimmune Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADAP#NASDAQ">ADAP</a>) with a Buy and maintains $4 price target.

News

Price Target

Reiteration

Analyst Ratings

ADAP

HC Wainwright & Co. Reiterates Buy on Adaptimmune Therapeutics, Maintains $4 Price Target

WIIM

Adaptimmune Therapeutics shares are trading higher. The company reported Q2 financial results.

Earnings

Adaptimmune Therapeutics Q2 2024 GAAP EPS $0.04 May Not Be Comparable To $(0.08) Estimate, Sales $128.231 May Not Be Comparable To $38.483M Estimate

Shares of Ainos, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIMD#NASDAQ">AIMD</a>) rose sharply in today's pre-market trading after the company announced that it has obtained exclusive licenses for a total of 10 invention patents and patent applications from Taiwan Carbon Nano Technology.
Ainos shares jumped 37.7% to $0.7200 in pre-market trading.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>LogicMark, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGMK#NASDAQ">LGMK</a>) rose 49% to $0.3201 in today's pre-market trading. On Aug. 5, LogicMark announced the closing of $4.5 million public offering priced at-the-market.</li>
<li>PS International Group Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSIG#NASDAQ">PSIG</a>) gained 27.7% to $1.29 in pre-market trading after jumping 46% on Friday.</li>
<li>Y-mAbs Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YMAB#NASDAQ">YMAB</a>) shares rose 27.3% to $14.28 in pre-market trading.</li>
<li>FSD Pharma Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUGE#NASDAQ">HUGE</a>) gained 24.5% to $0.2490 in pre-market trading. FSD Pharma shares jumped 118% on Friday after Celly Nutrition, which is backed by FSD Pharma, announced the upcoming launch of its &#8216;unbuzzd&#8217; recovery drink.</li>
<li>Genius Group Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GNS#NYSE">GNS</a>) gained 18.5% to $0.16. Genius Group shares gained around 8% on Friday after the company announced its board approved the purchase of up to 10 million shares by founder and CEO Roger James Hamilton.</li>
<li>ProMIS Neurosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PMN#NASDAQ">PMN</a>) gained 15.4% to $1.41 in pre-market trading. The company, last week, posted a narrower-than-expected quarterly loss.</li>
<li>Adaptimmune Therapeutics plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADAP#NASDAQ">ADAP</a>) jumped 12.8% to $1.12 in pre-market trading.</li>
<li>Esperion Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESPR#NASDAQ">ESPR</a>) gained 11.4% to $2.25 in pre-market trading.</li>
<li>AirNet Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANTE#NASDAQ">ANTE</a>) shares gained 10.1% to $0.2999 in pre-market trading after declining around 20% on Friday.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Meta Materials Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMAT#NASDAQ">MMAT</a>) shares declined 27.7% to $0.6810 in pre-market trading. Meta Materials shares dipped around 55% on Friday after the company disclosed in an SEC filing that it ceased operations and filed a voluntary petition for relief under the provisions of Chapter 7 of Title 11 in the US Bankruptcy Court.</li>
<li>iLearningEngines, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AILE#NASDAQ">AILE</a>) shares dipped 25.8% to $4.29 in pre-market trading. ILearningEngines will report financial results for the second quarter before the opening bell on Tuesday, Aug. 13.</li>
<li>Tenon Medical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNON#NASDAQ">TNON</a>) declined 16.9% to $0.49 in pre-market trading. Tenon Medical will release financial results for the second quarter after the closing bell on Aug. 13.</li>
<li>Sonoma Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNOA#NASDAQ">SNOA</a>) shares declined 15.4% to $0.21 in pre-market trading. Sonoma Pharmaceuticals shares dipped around 20% on Friday after the company reported worse-than-expected first-quarter financial results.</li>
<li>Humacyte, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUMA#NASDAQ">HUMA</a>) shares fell 13.4% to $6.85 in pre-market trading after the company announced that the FDA will require additional time to complete its review of the BLA for ATEV in the treatment of vascular trauma.</li>
<li>Big Tree Cloud Holdings Limited  (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DSY#NASDAQ">DSY</a>) shares fell 11.6% to $1.30 in pre-market trading after jumping 70% on Friday.</li>
<li>ENDRA Life Sciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDRA#NASDAQ">NDRA</a>) fell 11.1% to $0.0448 in pre-market trading. ENDRA Life Sciences will report financial results for the three and six months ended June 30 on Wednesday, Aug. 14.</li>
<li>CareMax, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMAX#NASDAQ">CMAX</a>) fell 7.7% to $4.19 in today's pre-market trading after the company reported worse-than-expected second-quarter results.</li>
<li>Hawaiian Electric Industries, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HE#NYSE">HE</a>) fell 7.7% to $14.28 pre-market trading after the company reported weak second-quarter earnings.</li>
<li>Pagaya Technologies Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGY#NASDAQ">PGY</a>) shares fell 6% to $13.37 in pre-market trading. The company reported second-quarter results on Friday.</li>
</ul>
Now Read This:<a href="https://www.benzinga.com/markets/24/08/40298443/wall-streets-most-accurate-analysts-give-their-take-on-3-defensive-stocks-delivering-high-dividend-y"> </a>
<ul>
<li><a href="https://www.benzinga.com/markets/24/08/40298443/wall-streets-most-accurate-analysts-give-their-take-on-3-defensive-stocks-delivering-high-dividend-y">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Defensive Stocks Delivering High-Dividend Yields</a></li>
</ul>

Pre-Market Outlook

Markets

Movers

Trading Ideas

AILE

AIMD

ANTE

CMAX

ESPR

MASSIVE INTERACTIVE NV by Massive Interactive, Inc.

HUGE

HUMA

LGMK

MMAT

NDRA

PSIG

SNOA

TNON

YMAB

Why Ainos Shares Are Trading Higher By Around 38%; Here Are 20 Stocks Moving Premarket

In the preceding three months, 4 analysts have released ratings for Adaptimmune Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADAP#NASDAQ">ADAP</a>), presenting a wide array of perspectives from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $3.54, a high estimate of $4.00, and a low estimate of $3.00. This current average represents a 45.54% decrease from the previous average price target of $6.50. 
<img src="https://www.benzinga.com/files/images/story/2024/1722870046_0_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Adaptimmune Therapeutics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arthur He</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$4.00</td>
<td>$4.00</td>
</tr>
<tr>
<td>Arthur He</td>
<td>HC Wainwright &amp; Co.</td>
<td>Announces</td>
<td>Buy</td>
<td>$4.00</td>
<td>-</td>
</tr>
<tr>
<td>George Farmer</td>
<td>Scotiabank</td>
<td>Announces</td>
<td>Sector Outperform</td>
<td>$3.15</td>
<td>-</td>
</tr>
<tr>
<td>Graig Suvannavejh</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Buy</td>
<td>$3.00</td>
<td>$9.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Adaptimmune Therapeutics. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Adaptimmune Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Adaptimmune Therapeutics's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Adaptimmune Therapeutics's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ADAP/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Adaptimmune Therapeutics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Get to Know Adaptimmune Therapeutics Better</h2>
Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70 and others for multiple cancer types.
<h3>Key Indicators: Adaptimmune Therapeutics's Financial Health</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Decline in Revenue: Over the 3 months period, Adaptimmune Therapeutics faced challenges, resulting in a decline of approximately -88.07% in revenue growth as of 31 March, 2024. This signifies a reduction in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Adaptimmune Therapeutics's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -854.23%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Adaptimmune Therapeutics's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -151.84%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Adaptimmune Therapeutics's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -17.94%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Adaptimmune Therapeutics's debt-to-equity ratio is notably higher than the industry average. With a ratio of 0.97, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>Analyst Ratings: What Are They?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Latest Analyst Ratings For Adaptimmune Therapeutics

Thursday, the FDA approved Adaptimmune Therapeutics plc&#8217;s&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADAP#NASDAQ">ADAP</a>) Tecelra (afamitresgene autoleucel) for unresectable or metastatic synovial sarcoma,&nbsp;a rare type of cancer that tends to occur near large joints, <a target="_blank" href="https://www.benzinga.com/pressreleases/24/08/b40120407/adaptimmune-receives-u-s-fda-accelerated-approval-of-tecelra-afamitresgene-autoleucel-the-first-ap" rel="noreferrer noopener">mainly the knees</a>.
The approval covers patients who have received prior chemotherapy, are HLA-A&#x2A;02:01P, -A&#x2A;02:02P, -A&#x2A;02:03P, or -A&#x2A;02:06P positive, and whose tumor expresses the MAGE-A4 antigen.
This indication is approved under accelerated approval based on the overall response rate and duration of response.
Tecelra is the first engineered cell therapy for a solid tumor cancer approved in the U.S. and the first new therapy option in more than a decade for synovial sarcoma.
Tecelra&#8217;s approval was based on the SPEARHEAD-1 (Cohort 1) trial results, which included 44 patients.
Tecelra treatment resulted in an ORR of 43% with a complete response rate of 4.5%. The median duration of response was six months.
Among patients who were responsive to the treatment, 39% had a duration of response of 12 months or longer.
Adaptimmune plans to have at least six to ten authorized treatment centers (ATCs) up and running this year and to onboard approximately 30 treatment centers within the first two years.
&#8220;TECELRA (afami-cel), which uses each patient&#8217;s own immune cells to recognize and attack their cancer cells in a one-time infusion treatment, is significantly different than the current standards of care for advanced synovial sarcoma,&#8221; said Sandra D&#8217;Angelo, SPEARHEAD Trial Principal Investigator.
In May, Galapagos NV (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLPG#NASDAQ">GLPG</a>) and&nbsp;Adaptimmune Therapeutics entered into a clinical collaboration agreement with an option to exclusively license Adaptimmune&#8217;s next-generation TCR T-cell therapy (uza-cel) targeting MAGE-A4 for head &amp; neck cancer and potential future solid tumor indications, using Galapagos&#8217; <a target="_blank" href="https://www.benzinga.com/pressreleases/24/05/g39097113/galapagos-and-adaptimmune-sign-clinical-collaboration-agreement-with-an-option-to-exclusively-lice" rel="noreferrer noopener">decentralized cell manufacturing platform</a>.
Adaptimmune to receive initial payments of $100 million, comprising $70 million upfront and $30 million of R&amp;D funding, option exercise fees of up to $100 million, additional development and sales milestone payments of up to a maximum of $465 million, plus tiered royalties on net sales.
Price Action: ADAP stock is up 7.09% at $1.36 during the premarket session at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/08/40110159/agios-pharmaceuticals-rare-blood-disorder-drug-misses-primary-goal-in-pediatric-study-stock-slide" target="_blank" rel="noreferrer noopener">Agios Pharmaceuticals&#8217; Rare Blood Disorder Drug Misses Primary Goal In Pediatric Study, Stock Slides</a>.</li>
</ul>

Biotech

Health Care

General

GLPG

FDA Approves Adaptimmune Therapeutics' Engineered Cell Therapy As First For Solid Tumor And New Therapy For Rare Soft Tissue Cancer In Over A Decade

Trading Halt: Halt status updated at 7:00:00 AM ET: Quotation Resumption: News and Resumption Times

<ul>
<li>Approved for advanced MAGE-A4+synovial sarcoma in adults with certain HLA types who have received prior chemotherapy</li>
<li>TECELRA is the first new treatment option for people with synovial sarcoma in more than a decade</li>
</ul>

Reported Earlier, Adaptimmune's TECELRA Gains U.S. FDA Accelerated Approval As First Engineered Cell Therapy For Solid Tumors

Trading Halt: Halted at 7:01:19 p.m. ET - Trading Halt: Halt News Pending

HC Wainwright &amp; Co. analyst Arthur He initiates coverage on Adaptimmune Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADAP#NASDAQ">ADAP</a>) with a Buy rating and announces Price Target of $4.

Initiation

HC Wainwright & Co. Initiates Coverage On Adaptimmune Therapeutics with Buy Rating, Announces Price Target of $4

By Michael Kim
<a href="https://s27.q4cdn.com/906368049/files/News/2024/Zacks_SCR_Research_06122024_ADAP_Kim.pdf">READ THE FULL ADAP RESEARCH REPORT</a>
We are initiating coverage of Adaptimmune Therapeutics plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/adap#NASDAQ">ADAP</a>) with a 12-month price target of $3.00, translating into sizeable upside from the stock&#39;s current price. Adaptimmune designs, develops, manufactures, and delivers innovative cell therapies via the company&#39;s unique T-cell receptor (TCR) platform to treat cancers across multiple solid tumor types.
Our investment thesis revolves around:
1. Unique T-cell therapy: Adaptimmune&#39;s mission is to transform cancer treatment by engineering naturally-occurring TCRs to better recognize and bind to specific cancer biomarkers and activate the immune system to target and eradicate cancer cells. Over the last 15+ years, the company has developed a proprietary technology platform that identifies cancer targets and genetically engineers a patient&#39;s TCRs to enhance efficacy, while avoiding healthy cells. Adaptimmune&#39;s cell therapies can be engineered from a patient&#39;s own T-cells (autologous) or manufactured from stem cells (allogeneic).
Adaptimmune&#39;s engineered T-cell therapy addresses solid tumor cancers. The first engineered T-cell products from Adaptimmune, afami-cel and lete-cel, will target soft tissue sarcomas (STSs), specifically synovial sarcoma and myxoid/round cell liposarcoma (MRCLS). Approximately 13,000 soft tissue sarcomas are diagnosed each year in the U.S., of which synovial sarcoma and MRCLS account for an estimated 1,000+ cases. Both cancers are characterized by lower survival rates and limited treatment options, and mostly impact younger people and middle-aged adults.
2. Commercialization inflection point: The pending launch of afami-cel (assuming FDA approval) marks the transition of Adaptimmune from a clinical-stage biopharmaceutical company to a commercial-stage cell therapy company. From the start, Adaptimmune has been constructed as an integrated company, with the vision of developing and delivering cell therapies to treat patients with cancer. The firm leverages integrated research, clinical development, translational sciences, manufacturing, and commercial capabilities to facilitate delivery in an efficient and timely manner. A key component of Adaptimmune&#39;s integrated approach is the company&#39;s in-house manufacturing facilities here in the U.S., as well as in the UK, that allow for scaling supply to meet demand and quickly iterating on process and supply chain improvements.
Adaptimmune&#39;s transition to commercialization will be led by afami-cel, the company&#39;s first engineered TCR T-cell therapy targeting the MAGE-A4 biomarker presented on HLA for treatment of synovial sarcoma. The FDA accepted Adaptimmune&#39;s Biologics License Application (BLA) for afami-cel with a Prescription Drug User Fee Act (PDUFA) date of August 4, 2024. Assuming FDA approval, the plan is to immediately launch afami-cel, with an initial focus on six to 10 Authorized Treatment Centers (ATCs), expanding to 30 ATCs across the U.S. over the following 18 to 24 months leveraging the company&#39;s established infrastructure and relationships. Looking ahead, we see opportunities for afami-cel to target other sarcomas and/or expand into different geographies.
3. Robust product pipeline: Adaptimmune maintains a diversified pipeline of late-stage programs, as well as a deep preclinical pipeline across multiple autologous and allogeneic cell therapies. From an R&amp;D perspective, Adaptimmune maintains alliances with several cancer centers of excellence focused on a number of clinical and preclinical studies for the development of T-cell therapies for multiple types of cancer including bladder, lung, ovarian, head and neck, melanoma, esophageal, and gastric indications.
<img src="//s27.q4cdn.com/906368049/files/pictures/2024/06122024_ADAP_1.png" style="width:650px" />
4. Powerful economic opportunity: While we expect Adaptimmune to report net losses through for the next couple of years, the key driver for an inflection in net income remains how quickly afami-cel sales ramp up (assuming FDA approval). Our model assumes related sales start in 4Q24, with ~$80 million of gross sales in 2025. Management is targeting $400 million of peak sales for ADAP&#39;s sarcoma franchise (afami-cel and lete-cel), with peak gross margins of 70%. Importantly, there are no other engineered cell therapies developed to treat solid tumors on the market. Over time, we expect operating leverage to build as revenues scale, particularly as the commercialization of lete-cel will follow similar development and distribution approaches as afami-cel.
From a capital perspective, current liquidity, upcoming revenue from the launch of afami-cel, and several $25 million tranches of the recently announced $125 million term loan facility are likely sufficient to fund operations into late 2025. Additionally, Adaptimmune is eligible to receive $100 million of initial payments as part of the recently announced clinical collaboration agreement with Galapagos NV. Furthermore, management can opt to tap the company&#39;s $200 million at-the-market (ATM) facility ($171 million available as of 3/6/24).
5. Probability-weighted DCF model points to meaningful upside for the stock: We are initiating coverage of Adaptimmune Therapeutics plc with a price target of $3.00 representing meaningful upside potential from the stock&#39;s current price. Our price target is based on a probability-weighted DCF model incorporating the company&#39;s three late-stage clinical programs currently underway (afami-cel, lete-cel, and uza-cel for ovarian cancer), with a near-term eligible patient population of ~4,600 per year (afami-cel and lete-cel in the U.S. + ovarian uza-cel in the U.S. and Europe). Importantly, our valuation work does not incorporate head &amp; neck and bladder indications for uza-cel, PRAME, or CD70 &ndash; all targeting much larger indications, but not as far along the development curve.
Our report provides a deep dive into Adaptimmune&#39;s unique T-cell therapy platform, commercialization strategy, and robust product pipeline. In addition, we introduce the senior management team, and walk through our financial model and valuation analysis. The final section summarizes what we believe to be key investment risks specific to FDA approval and commercialization processes, ongoing funding needs, manufacutring capacity, and strategic/financial partnerships.

Penny Stocks

ADAP: Initiating Coverage of Adaptimmune, a Leading T-Cell Therapy Company

Shares of SentinelOne, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/S#NYSE">S</a>) shares fell sharply during Friday's session after the company posted <a href="https://www.benzinga.com/news/earnings/24/05/39100292/sentinelone-reports-mixed-q1-results-eps-miss-sales-beat">mixed first-quarter results.</a>
SentinelOne reported quarterly losses of 23 cents per share, which missed the analyst consensus estimate of losses of 5 cents by 360%. Quarterly sales came in at $186.4 million which beat the analyst consensus estimate of $181.09 million by 2.93%, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
SentinelOne shares dipped 15.9% to $16.35 on Friday.
Here are some other stocks moving in today&#8217;s mid-day session.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Novo Integrated Sciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVOS#NASDAQ">NVOS</a>) shares jumped 130.6% to $1.04 after the company approved a $5 million stock repurchase. The company&#8217;s board is conducting a review to determine whether it is appropriate to increase the amount under the repurchase program.</li>
<li>Latam Logistic Properties, S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LPA#NYSE">LPA</a>) rose 79.5% to $464.77.</li>
<li>Digital Health Acquisition Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DHAC#NASDAQ">DHAC</a>) gained 57.3% to $23.60.</li>
<li>Brand Engagement Network, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNAI#NASDAQ">BNAI</a>) gained 51% to $3.89.</li>
<li>XChange Tec Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XHG#NASDAQ">XHG</a>) gained 41.5% to $0.9691 after dipping 15% on Thursday.</li>
<li>Nuburu, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BURU#NYSE">BURU</a>) jumped 39.2% to $0.2226 after falling around 12% on Thursday.</li>
<li>FOXO Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FOXO#NYSE">FOXO</a>) gained 30% to $0.4432.</li>
<li>LightInTheBox Holding Co., Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LITB#NYSE">LITB</a>) rose 27.4% to $0.65.</li>
<li>Vaccinex, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCNX#NASDAQ">VCNX</a>) gained 26% to $6.57.</li>
<li>Ambarella, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMBA#NASDAQ">AMBA</a>) rose 23% to $59.42 following strong first-quarter earnings and upbeat second-quarter guidance.</li>
<li>The Gap, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPS#NYSE">GPS</a>) shares climbed 21.6% to $27.38 after reporting strong quarterly results.</li>
<li>Innovative Eyewear, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUCY#NASDAQ">LUCY</a>) shares gained 21.5% to $0.9602. Innovative Eyewear recently launched its Eddie Bauer Smart Eyewear collection.</li>
<li>DigiAsia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FAAS#NASDAQ">FAAS</a>) gained 19.2% to $8.38.</li>
<li>AC Immune SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACIU#NASDAQ">ACIU</a>) rose 16.6% to $4.6310. BTIG analyst Thomas Shrader initiated coverage on AC Immune with a Buy rating and announced a price target of $8.</li>
<li>Larimar Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRMR#NASDAQ">LRMR</a>) gained 13.9% to $8.09. Larimar Therapeutics was selected by the FDA to participate in START Pilot Program for Nomlabofusp in Friedreich&#8217;s Ataxia.</li>
<li>DoubleDown Interactive Co., Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DDI#NASDAQ">DDI</a>) rose 13.1% to $13.80.</li>
<li>American Superconductor Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMSC#NASDAQ">AMSC</a>) jumped 11% to $19.35.</li>
<li>PagerDuty, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PD#NYSE">PD</a>) gained 10.7% to $19.87 following a first-quarter earnings beat.</li>
<li>A2Z Smart Technologies Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZ#NASDAQ">AZ</a>) shares gained 10% to $0.44. </li>
<li>V.F. Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VFC#NYSE">VFC</a>) rose 10% to $13.57 after the company appointed former Lululemon Chief Product Officer Michelle Choehas as the Global Brand President of Vans.</li>
<li>Elastic N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESTC#NASDAQ">ESTC</a>) gained 9.6% to $102.09 following a fourth-quarter earnings beat.</li>
<li>Adaptimmune Therapeutics plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADAP#NASDAQ">ADAP</a>) gained 9% to $1.10 after the company and Galapagos entered a clinical collaboration to license Adaptimmune&#8217;s uza-cel in in head &amp; neck cancer.</li>
<li>Zscaler, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZS#NASDAQ">ZS</a>) rose 8.6% to $170.04 after the company reported better-than-expected third-quarter earnings.</li>
<li>flyExclusive, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLYX#NASDAQ">FLYX</a>) climbed 7.6% to $5.64. flyExclusive announced the appointment of two key business leaders.</li>
<li>Asana, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASAN#NYSE">ASAN</a>) rose 4.3% to $13.70. Asana posted a narrower-than-expected loss for its first quarter, while sales topped estimates.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Smart for Life, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMFL#NASDAQ">SMFL</a>) fell 38.7% to $3.71.</li>
<li>Sify Technologies Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIFY#NASDAQ">SIFY</a>) shares fell 38.1% to $1.0398 after gaining over 8% on Thursday.</li>
<li>Calidi Biotherapeutics, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLDI#NYSE">CLDI</a>) dipped 31.1% to $0.2073 after the company reported exercise of warrants for $2.1 million gross proceeds.</li>
<li>MongoDB, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDB#NASDAQ">MDB</a>) shares dipped 26.2% to $228.83 after the company issued weak FY25 guidance.</li>
<li>Summit Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>) shares fell 25.2% to $8.16. Summit Therapeutics jumped 272% on Thursday after the company&#8217;s Phase III HARMONi-2 trial met its primary endpoint.</li>
<li>Loop Media, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LPTV#NYSE">LPTV</a>) fell 21.3% to $0.1817. Loop Media priced $2.45 million registered direct offering of 9.65 million shares of common stock at a price of $0.15 per share.</li>
<li>Dell Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>) shares fell 21.2% to $134.18. Dell reported upbeat earnings and sales results for the first quarter.</li>
<li>Lotus Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOT#NASDAQ">LOT</a>) fell 21% to $10.30. Lotus Technology recently reported a year-over-year increase in first-quarter sales results.</li>
<li>Montana Technologies Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIRJ#NASDAQ">AIRJ</a>) dipped 17.8% to $12.84.</li>
<li>Kintara Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTRA#NASDAQ">KTRA</a>) fell 16.7% to $0.2639 after gaining over 16% on Thursday.</li>
<li>Pulse Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLSE#NASDAQ">PLSE</a>) dipped 15.7% to $10.15.</li>
<li>Knightscope, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KSCP#NASDAQ">KSCP</a>) fell 15.3% to $0.2546.</li>
<li>Phreesia, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHR#NYSE">PHR</a>) fell 13.3% to $18.47 following first-quarter results.</li>
<li>JE Cleantech Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JCSE#NASDAQ">JCSE</a>) shares fell 12% to $1.1450 after gaining around 85% on Thursday.</li>
<li>Momentus Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNTS#NASDAQ">MNTS</a>) shares fell 11.9% to $0.7620. Momentus received Nasdaq deficiency notice due to delayed Form 10-Q.</li>
<li>Genfit S.A. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNFT#NASDAQ">GNFT</a>) shares fell 11.7% to $5.27 after gaining 13% on Thursday.</li>
<li>Marvell Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>) fell 11.3% to $68.11 following worse-than-expected first-quarter earnings.</li>
<li>Veeva Systems Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) shares fell 10.8% to $173.19 after the company issued weak revenue guidance.</li>
<li>Fitell Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTEL#NASDAQ">FTEL</a>) declined 10.6% to $15.20.</li>
<li>OneMedNet Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONMD#NASDAQ">ONMD</a>) shares declined 10.3% to $2.3420. OneMedNet shares jumped 34% on Thursday after the company announced that it has entered into a non-exclusive three-year Master Services Agreement with an undisclosed U.S.-based medical technology company.</li>
<li>Mesa Laboratories, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLAB#NASDAQ">MLAB</a>) fell 10.1% to $99.19. Mesa Laboratories has delayed the release of its fourth-quarter and fiscal year 2024 financial results, originally scheduled for today.</li>
<li>Vertiv Holdings Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRT#NYSE">VRT</a>) dipped 9.2% to $92.84.</li>
<li>Vistra Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VST#NYSE">VST</a>) declined 9% to $95.84.</li>
<li>HP Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPQ#NYSE">HPQ</a>) fell 7.6% to $35.44. HP recently posted better-than-expected second-quarter financial results.</li>
<li>Super Micro Computer, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) declined 7.2% to $768.22.</li>
<li>Trump Media &amp; Technology Group Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>) shares declined 4.9% to $49.31 after the jury reached a verdict in Donald Trump&#8217;s hush money case.</li>
</ul>
Now Read This: &lt;a href=&#8221;https://www.benzinga.com/news/earnings/24/04/38312420/how-to-earn-500-a-month-from-ford-stock-ahead-of-q1-earnings-report&#8221;&gt;&lt;em&gt; How To Earn $500 A Month From Ford Stock Ahead Of Q1 Earnings Report&lt;/em&gt;&lt;/a&gt;

Intraday Update

ACIU

AIRJ

AMBA

AMSC

ASAN

BNAI

BURU

CLDI

DELL

DHAC

ESTC

FAAS

FLYX

FOXO

FTEL

GNFT

JCSE

KSCP

Kintara Therapeutics, Inc. - Common Stock

KTRA

LITB

LPTV

Larimar Therapeutics, Inc. - Common Stock

LRMR

LUCY

MLAB

MNTS

MRVL

NVOS

ONMD

PLSE

SIFY

SMCI

SMFL

SMMT

VCNX

VEEV

Why SentinelOne Shares Are Trading Lower By 16%? Here Are Other Stocks Moving In Friday's Mid-Day Session

Adaptimmune Therapeutics PLC &#8211; ADR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADAP#NASDAQ">ADAP</a>) shares are trading higher by 15.8% to $1.17 during Friday&#8217;s session after the company and Galapagos entered a clinical collaboration to license Adaptimmune&#8217;s uza-cel in <a href="https://www.benzinga.com/pressreleases/24/05/g39097113/galapagos-and-adaptimmune-sign-clinical-collaboration-agreement-with-an-option-to-exclusively-lice">head &amp; neck cancer</a>.
Uza-cel, which has shown an 80% response rate in a Phase 1 trial, is engineered to express the CD8α co-receptor, enhancing the immune response against tumors.&nbsp;
The collaboration will utilize Galapagos&#8217; decentralized cell manufacturing platform, which may improve the efficacy and durability of uza-cel and enable faster treatment delivery, with a vein-to-vein time of seven days.
See Also: <a href="https://www.benzinga.com/economics/macro-economic-events/24/05/39110198/feds-preferred-inflation-gauge-matches-estimates-personal-income-spending-slow-mo">Fed&#8217;s Preferred Inflation Gauge Matches Estimates; Personal Spending Slows More Than Predicted</a>
<h2 class="wp-block-heading">How To Buy ADAP Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Adaptimmune Therapeutics&#8217; case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, ADAP has a 52-week high of $2.05 and a 52-week low of $0.42.

Why Adaptimmune Therapeutics (ADAP) Stock Is Moving

<h3>Gainers</h3>
<ul>
<li>Novo Integrated Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVOS#NASDAQ">NVOS</a>) stock moved upwards by 69.6% to $0.77 during Friday's pre-market session. The company's market cap stands at $14.5 million. </li>
<li>Adaptimmune Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADAP#NASDAQ">ADAP</a>) shares moved upwards by 40.59% to $1.42. The market value of their outstanding shares is at $362.8 million. </li>
<li>Bionomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNOX#NASDAQ">BNOX</a>) shares moved upwards by 29.56% to $1.28. The market value of their outstanding shares is at $13.6 million. </li>
<li>Innovative Eyewear (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUCY#NASDAQ">LUCY</a>) shares moved upwards by 27.84% to $1.01. The market value of their outstanding shares is at $17.6 million. </li>
<li>Xtant Medical Hldgs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/XTNT#AMEX">XTNT</a>) stock moved upwards by 20.97% to $0.9. The market value of their outstanding shares is at $117.3 million. </li>
<li>Bright Green (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BGXX#NASDAQ">BGXX</a>) shares increased by 18.16% to $0.26. The company's market cap stands at $50.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Summit Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>) stock decreased by 17.9% to $8.97 during Friday's pre-market session. The company's market cap stands at $6.2 billion. </li>
<li>Genfit (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNFT#NASDAQ">GNFT</a>) stock declined by 11.15% to $5.26. The market value of their outstanding shares is at $262.2 million. </li>
<li>Pulse Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLSE#NASDAQ">PLSE</a>) stock decreased by 10.79% to $10.75. The company's market cap stands at $593.6 million. </li>
<li>Sonoma Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNOA#NASDAQ">SNOA</a>) stock fell 10.25% to $0.18. The company's market cap stands at $2.8 million. </li>
<li>Veeva Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) shares declined by 9.11% to $176.5. The company's market cap stands at $28.5 billion. As per the press release, Q1 earnings came out yesterday. </li>
<li>OneMedNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONMD#NASDAQ">ONMD</a>) stock declined by 8.43% to $2.39. The company's market cap stands at $57.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BGXX

BNOX

XTNT

12 Health Care Stocks Moving In Friday's Pre-Market Session

Adaptimmune Therapeutics shares are trading higher after the company and Galapagos entered a clinical collaboration to license Adaptimmune's uza-cel in in head & neck cancer.

Shares of Zscaler, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZS#NASDAQ">ZS</a>) rose sharply in today's pre-market trading after the company reported <a href="https://www.benzinga.com/news/earnings/24/05/39099632/zscaler-q3-earnings-revenue-eps-exceed-estimates-driven-by-growing-customer-interest-in-zero-trust-">better-than-expected third-quarter earnings.</a>
Zscaler said third-quarter revenue increased 32% year-over-year to $553.2 million, which beat the consensus estimate of $535.906 million, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. The company reported quarterly adjusted earnings of 88 cents per share, beating analyst estimates of 66 cents per share.
Zscaler shares jumped 17.5% to $184.12 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Nuburu, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BURU#NYSE">BURU</a>) rose 71.9% to $0.2750 in today's pre-market trading after falling around 12% on Thursday.</li>
<li>XChange Tec Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XHG#NASDAQ">XHG</a>) shares gained 64.9% to $1.13 in pre-market trading after dipping 15% on Thursday.</li>
<li>Novo Integrated Sciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVOS#NASDAQ">NVOS</a>) gained 49.9% to $0.6760 in pre-market trading following HSBC‘s confirmation of a $78 million Standby Letter of Credit.</li>
<li>Adaptimmune Therapeutics plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADAP#NASDAQ">ADAP</a>) gained 29.7% to $1.31 in pre-market trading after the company and Galapagos entered a clinical collaboration to license Adaptimmune&#8217;s uza-cel in in head &amp; neck cancer.</li>
<li>Cue Health Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLTH#NASDAQ">HLTH</a>) shares rose 27.6% to $0.0925 in pre-market trading after gaining 32% on Thursday. Cue Health recently announced that it filed voluntary petitions under Chapter 7 of the U.S. Bankruptcy Code in the District of Delaware to pursue a wind down of its business.</li>
<li>A2Z Smart Technologies Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZ#NASDAQ">AZ</a>) shares gained 22.3% to $0.4890 in pre-market trading.  </li>
<li>The Gap, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPS#NYSE">GPS</a>) shares climbed 21.9% to $27.45 in pre-market trading after reporting strong quarterly results</li>
<li>Faraday Future Intelligent Electric Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFIE#NASDAQ">FFIE</a>) gained 20.2% to $0.6799 in pre-market trading after jumping 27% on Thursday. Faraday Future Intelligent Electric recently reported worse-than-expected FY23 sales results and announced that it is withdrawing its production target guidance.</li>
<li>Asana, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASAN#NYSE">ASAN</a>) rose 10.9% to $14.56 in pre-market trading. Asana posted a narrower-than-expected loss for its first quarter, while sales topped estimates.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Sify Technologies Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIFY#NASDAQ">SIFY</a>) shares declined 40.4% to $1.00 in pre-market trading after gaining over 8% on Thursday.</li>
<li>Summit Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>) shares declined 34.6% to $7.14 in pre-market trading. Summit Therapeutics jumped 272% on Thursday after the company&#8217;s Phase III HARMONi-2 trial met its primary endpoint.</li>
<li>MongoDB, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDB#NASDAQ">MDB</a>) shares dipped 24.5% to $234.00 in pre-market trading after the company issued weak FY25 guidance.</li>
<li>JE Cleantech Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JCSE#NASDAQ">JCSE</a>) shares fell 15.4% to $1.10 in pre-market trading after gaining around 85% on Thursday.</li>
<li>Dell Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>) shares fell 13.9% to $146.38 in pre-market trading. Dell reported upbeat earnings and sales results for the first quarter.</li>
<li>SentinelOne, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/S#NYSE">S</a>) shares fell 13.4% to $16.81 in pre-market trading after the company posted mixed first-quarter results.</li>
<li>Genfit S.A. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNFT#NASDAQ">GNFT</a>) shares fell 12.4% to $5.23 in pre-market trading after gaining 13% on Thursday.</li>
<li>Momentus Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNTS#NASDAQ">MNTS</a>) shares fell 12.1% to $0.7610 in pre-market trading. Momentus received Nasdaq deficiency notice due to delayed Form 10-Q.</li>
<li>Kintara Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTRA#NASDAQ">KTRA</a>) fell 11.9% to $0.2793 in pre-market trading after gaining over 16% on Thursday.</li>
<li>OneMedNet Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONMD#NASDAQ">ONMD</a>) shares declined 11.5% to $2.31 in pre-market trading. OneMedNet shares jumped 34% on Thursday after the company announced that it has entered into a non-exclusive three-year Master Services Agreement with an undisclosed U.S.-based medical technology company.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/news/earnings/24/05/39104172/dell-asana-and-3-stocks-to-watch-heading-into-friday">Dell, Asana And 3 Stocks To Watch Heading Into Friday</a>

FFIE

HLTH

Why Zscaler Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket

<h3>Gainers</h3>
<ul>
<li>MyMD Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYMD#NASDAQ">MYMD</a>) stock rose 46.0% to $2.89 during Thursday's after-market session. The market value of their outstanding shares is at $6.6 million. </li>
<li>Adaptimmune Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADAP#NASDAQ">ADAP</a>) stock moved upwards by 31.68% to $1.33. The market value of their outstanding shares is at $339.8 million. </li>
<li>China Pharma Holdings, Inc. Common Stock (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CPHI#AMEX">CPHI</a>) shares moved upwards by 12.83% to $0.33. </li>
<li>BiomX (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PHGE#AMEX">PHGE</a>) stock rose 6.24% to $0.44. The market value of their outstanding shares is at $31.0 million. </li>
<li>Virios Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIRI#NASDAQ">VIRI</a>) stock increased by 6.12% to $0.22. The market value of their outstanding shares is at $6.1 million. </li>
<li>Accuray (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARAY#NASDAQ">ARAY</a>) stock increased by 5.73% to $1.66. The company's market cap stands at $164.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Veeva Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) stock fell 7.8% to $179.0 during Thursday's after-market session. The company's market cap stands at $28.9 billion. The company's, Q1 earnings came out today. </li>
<li>Intelligent Bio Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INBS#NASDAQ">INBS</a>) shares fell 6.64% to $2.23. The company's market cap stands at $6.9 million. </li>
<li>Reshape Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RSLS#NASDAQ">RSLS</a>) stock decreased by 6.6% to $0.23. The market value of their outstanding shares is at $5.4 million. </li>
<li>OneMedNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONMD#NASDAQ">ONMD</a>) stock decreased by 6.14% to $2.45. The company's market cap stands at $58.4 million. </li>
<li>Cosmos Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COSM#NASDAQ">COSM</a>) stock fell 5.0% to $0.66. The market value of their outstanding shares is at $11.0 million. </li>
<li>Abeona Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABEO#NASDAQ">ABEO</a>) stock fell 4.99% to $4.0. The company's market cap stands at $164.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ABEO

ARAY

COSM

CPHI

Intelligent Bio Solutions Inc. - Common Stock

INBS

MyMD Pharmaceuticals, Inc. - Common Stock

MYMD

PHGE

RSLS

VIRI

12 Health Care Stocks Moving In Thursday's After-Market Session

<ul>
<li>Adaptimmune and Galapagos to conduct clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel (next generation MAGE-A4 TCR T-cell therapy) produced on Galapagos' decentralized manufacturing platform in patients with head &amp; neck cancer</li>
<li>Uza-cel has shown encouraging results in head &amp; neck cancer with partial responses in four out of five patients to date in a Phase 1 trial using Adaptimmune's centralized manufacturing platform</li>
<li>Initial in vitro testing of uza-cel produced on Galapagos' decentralized manufacturing platform has shown encouraging data that support further clinical development</li>
<li>Adaptimmune to receive initial payments of $100 million, comprising $70 million upfront and $30 million of R&amp;D funding, option exercise fees of up to $100 million, additional development and sales milestone payments of up to a maximum of $465 million, plus tiered royalties on net sales</li>
<li>Galapagos has been granted an option to exclusively license uza-cel for global development and commercialization in head &amp; neck cancer, and potential future solid tumor cancer indications</li>
</ul>

Galapagos And Adaptimmune Enter Clinical Collaboration To License Next-Generation TCR T-Cell Therapy For Cancer Using Decentralized Manufacturing Platform

Earnings summary: Adaptimmune Therapeutics beats Q2 estimates

Adaptimmune Therapeutics plc (ADAP) Q2 2024 Earnings Call Transcript

TD Cowen analyst Marc Frahm has maintained their bullish stance on ADAP stock, giving a Buy rating on August 6. Marc Frahm has given his Buy rating...

Buy Rating Justified by Adaptimmune's Promising Financials and Strong Product Launch Prospects

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Adaptimmune Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/adap-stock-quote/">ADAP</a>) just reported results for the second quarter of 2024.<ul><li>Adaptimmune Therapeutics reported earnings per share of 24 cents. This was above the analyst estimate for EPS of -8 cents.</li><li>The company reported revenue of $128.23 million.</li><li>This was 233.24% better than the analyst estimate for revenue of $38.48 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/adap-stock-earnings-adaptimmune-therapeutics-for-q2-of-2024/">ADAP Stock Earnings: Adaptimmune Therapeutics Beats EPS, Beats Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

ADAP Stock Earnings: Adaptimmune Therapeutics Beats EPS, Beats Revenue for Q2 2024

In a report released today, Peter Lawson from Barclays assigned a Sell rating to Adaptimmune Therapeutics (ADAP – Research Report), with a price ta...

Adaptimmune Therapeutics (ADAP) Gets a Sell from Barclays

Analyst Arthur He CFA from H.C. Wainwright maintained a Buy rating on Adaptimmune Therapeutics (ADAP – Research Report) and keeping the price targe...

Buy Rating Affirmed for Adaptimmune Therapeutics Amidst Promising Product Launch and Strong Pipeline

Scotiabank analyst George Farmer maintained a Buy rating on Adaptimmune Therapeutics (ADAP – Research Report) today and set a price target of $3.15...

Scotiabank Sticks to Its Buy Rating for Adaptimmune Therapeutics (ADAP)

Leerink Partners analyst Jonathan Chang reiterated a Hold rating on Adaptimmune Therapeutics (ADAP – Research Report) yesterday and set a price tar...

Hold Rating on Adaptimmune Amid Commercialization and Financial Uncertainties

Galapagos: CAR-T Biotech To Change Landscape With GLPG5101 And Beyond

Adaptimmune's T-Cell Therapy Journey: A Small Market, Big Ambitions

GLPGF

Press Releases

Garry Menzel joins GHO Capital as Operating Partner

Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively license Adaptimmune's TCR T-cell therapy candidate, uza-cel, in head & neck cancer and potential future solid tumor indications

Adaptimmune and Galapagos Sign Clinical Collaboration Agreement with an Option to Exclusively License Adaptimmune's TCR T-cell Therapy Candidate, uza-cel, in Head & Neck Cancer and Potential Future Solid Tumor Indications

Intelligent Bio Solutions Inc. (NASDAQ: INBS) Advancing US FDA Process, Featured Among Top Health Care Movers

Adaptimmune to Present Data from Planned Interim Analysis of Pivotal IGNYTE-ESO Trial with Lete-cel at ASCO; Data Continue to Support further Development of Sarcoma Franchise

Adaptimmune Receives U.S. FDA Accelerated Approval of TECELRA® (afamitresgene autoleucel), the First Approved Engineered Cell Therapy for a Solid Tumor

Comments

Adaptimmune Therapeutics

Notizie

Ultime notizie per Adaptimmune Therapeutics (NASDAQ:ADAP) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO